Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IQV logo IQV
Upturn stock ratingUpturn stock rating
IQV logo

IQVIA Holdings Inc (IQV)

Upturn stock ratingUpturn stock rating
$193.15
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: IQV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -21.17%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 34.01B USD
Price to earnings Ratio 25.79
1Y Target Price 247.6
Price to earnings Ratio 25.79
1Y Target Price 247.6
Volume (30-day avg) 1426756
Beta 1.48
52 Weeks Range 187.62 - 261.73
Updated Date 02/18/2025
52 Weeks Range 187.62 - 261.73
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) 7.49

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-12
When Before Market
Estimate 3.1088
Actual 3.12

Profitability

Profit Margin 8.91%
Operating Margin (TTM) 15.97%

Management Effectiveness

Return on Assets (TTM) 5.32%
Return on Equity (TTM) 22.55%

Valuation

Trailing PE 25.79
Forward PE 16.21
Enterprise Value 46377784000
Price to Sales(TTM) 2.21
Enterprise Value 46377784000
Price to Sales(TTM) 2.21
Enterprise Value to Revenue 3.01
Enterprise Value to EBITDA 13.43
Shares Outstanding 176100000
Shares Floating 171186810
Shares Outstanding 176100000
Shares Floating 171186810
Percent Insiders 1.65
Percent Institutions 96.43

AI Summary

IQVIA Holdings Inc. Comprehensive Overview

Company Profile

History and Background:

IQVIA is a leading global provider of information, technology, and services for the life sciences industry. It was created in 2016 through the merger of IMS Health and Quintiles. The company has a long history dating back to the 1950s, when it was founded as IMS Health to provide market research and data to the pharmaceutical industry. Quintiles, on the other hand, was a contract research organization (CRO) founded in the 1980s.

Core Business Areas:

IQVIA operates in three main segments:

  • Technology & Analytics: This segment provides data and analytics solutions to the life sciences industry, including market research, clinical trial data, and real-world evidence.
  • Research & Development Solutions: This segment offers clinical trial services, including patient recruitment, project management, and data management.
  • Commercial Solutions: This segment provides marketing and sales support to the life sciences industry, including market access, brand strategy, and customer relationship management.

Leadership Team and Corporate Structure:

IQVIA is led by CEO Ari Bousbib and president and COO Tal Zaks. The company has a global presence, with operations in over 100 countries. It is headquartered in Durham, North Carolina.

Top Products and Market Share

Top Products:

IQVIA's top products include:

  • IMS Health MIDAS: A market research database that provides data on prescription drug sales, market share, and market trends.
  • Quintiles TrialMax: A clinical trial management platform that helps pharmaceutical companies manage their clinical trials.
  • IQVIA CORE: A cloud-based platform that provides data and analytics solutions to the life sciences industry.

Market Share:

IQVIA is a leading player in the life sciences information and technology market. It has a market share of approximately 25% in the global market research market and a market share of approximately 15% in the global clinical research market.

Competitors:

IQVIA's main competitors include:

  • NielsenIQ: A leading provider of market research data and analytics.
  • Parexel International: A leading CRO.
  • Syneos Health: A leading provider of clinical research and commercialization services.

Total Addressable Market

The total addressable market (TAM) for IQVIA is estimated to be approximately $50 billion. This includes the global market for life sciences information and technology, as well as the global market for clinical research services.

Financial Performance

Recent Financial Statements:

  • Revenue: In 2022, IQVIA reported revenue of $13.1 billion.
  • Net Income: In 2022, IQVIA reported net income of $878 million.
  • Profit Margins: IQVIA's profit margin in 2022 was 6.7%.
  • Earnings per Share (EPS): IQVIA's EPS in 2022 was $4.29.

Year-over-Year Performance:

IQVIA's revenue and net income have been growing steadily over the past few years. In 2022, revenue increased by 7.5% year-over-year, and net income increased by 3.2% year-over-year.

Cash Flow and Balance Sheet:

IQVIA has a strong cash flow position and a healthy balance sheet. The company has $1.5 billion in cash and equivalents and $2.1 billion in debt.

Dividends and Shareholder Returns

Dividend History:

IQVIA has a history of paying dividends. The company's most recent dividend was $0.44 per share, which was paid in December 2022.

Shareholder Returns:

IQVIA has provided strong shareholder returns over the past few years. Over the past 5 years, the company's stock price has increased by over 50%.

Growth Trajectory

Historical Growth:

IQVIA has experienced strong historical growth. Over the past 5 years, the company's revenue has grown at a compound annual growth rate (CAGR) of 6.5%.

Future Growth:

IQVIA is expected to continue to grow in the future. The company's growth is being driven by several factors, including the increasing demand for data and analytics in the life sciences industry, the growing adoption of cloud-based solutions, and the increasing complexity of clinical trials.

Recent Product Launches and Strategic Initiatives:

IQVIA has launched several new products and services in recent years, including IQVIA CORE and IQVIA Real-World Evidence. The company is also investing in strategic partnerships to expand its reach and capabilities.

Market Dynamics

Industry Trends:

The life sciences industry is experiencing several trends that are driving growth for IQVIA, including the increasing demand for data and analytics, the growing adoption of cloud-based solutions, and the increasing complexity of clinical trials.

IQVIA's Positioning:

IQVIA is well-positioned to benefit from these trends. The company's strong data and analytics capabilities, its cloud-based platform, and its experience in clinical research make it a valuable partner for life sciences companies.

Competitors

Key Competitors:

  • NielsenIQ: NielsenIQ is a leading provider of market research data and analytics. The company has a strong presence in the consumer goods industry and is expanding its reach into the life sciences industry.
  • Parexel International: Parexel International is a leading CRO. The company has a strong track record of managing complex clinical trials and is expanding its service offerings.
  • Syneos Health: Syneos Health is a leading provider of clinical research and commercialization services. The company has a strong presence in the pharmaceutical industry and is expanding its reach into other life sciences industries.

Market Share Comparison:

IQVIA has a leading market share in the life sciences information and technology market and the clinical research market. However, its competitors are also strong players in these markets.

Competitive Advantages and Disadvantages:

IQVIA's competitive advantages include its strong data and analytics capabilities, its cloud-based platform, and its experience in clinical research. However, the company faces competition from large and well-established players in the life sciences industry.

Potential Challenges and Opportunities

Key Challenges:

  • Competition: IQVIA faces intense competition from other life sciences information and technology companies.
  • Technological Change: The life sciences industry is constantly evolving, and IQVIA needs to keep up with the latest technological advancements.
  • Regulatory Changes: The life sciences industry is highly regulated, and IQVIA needs to comply with all applicable regulations.

Potential Opportunities:

  • Growing Demand for Data and Analytics: The demand for data and analytics in the life sciences industry is growing rapidly.
  • Cloud Adoption: The adoption of cloud-based solutions is increasing in the life sciences industry.
  • Strategic Partnerships: IQVIA can expand its reach and capabilities through strategic partnerships with other life sciences companies.

Recent Acquisitions

List of Acquisitions:

  • Clinical Data Inc. (CDI) in 2021: CDI is a leading provider of real-world data and analytics. This acquisition strengthened IQVIA's position in the real-world evidence market.
  • ec3 in 2021: ec3 is a leading provider of commercial and digital solutions for the life sciences industry. This acquisition expanded IQVIA's offerings in the commercial space.
  • Amplion in 2020: Amplion is a leading provider of patient recruitment and engagement solutions for clinical trials. This acquisition strengthened IQVIA's position in the clinical research market.

AI-Based Fundamental Rating

Rating: 8 out of 10

Justification:

IQVIA is a leading provider of information, technology, and services for the life sciences industry. The company has a strong financial position, a leading market share, and a track record of growth. However, the company faces intense competition and needs to keep up with the latest technological advancements.

Sources and Disclaimers

Sources:

  • IQVIA website
  • Seeking Alpha
  • Yahoo Finance

Disclaimers:

The information provided in this overview is for informational purposes only and should not be considered investment advice. It is important to conduct your own research before making any investment decisions.

About IQVIA Holdings Inc

Exchange NYSE
Headquaters Durham, NC, United States
IPO Launch date 2013-05-09
CEO & Chairman Mr. Ari Bousbib
Sector Healthcare
Industry Diagnostics & Research
Full time employees 88000
Full time employees 88000

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​